Advanced Enzyme Technologies Ltd AI Stock Analysis
Want to see IN:ADVENZYMES full AI Analyst Report?
Advanced Enzyme Technologies Ltd (ADVENZYMES) AI Stock Analysis
Advanced Enzyme Technologies Ltd
(NSE:ADVENZYMES)
The score is driven primarily by strong financial quality—minimal leverage, healthy profitability, and solid cash generation. This is tempered by weaker longer-term technical signals (below key medium/long moving averages with negative MACD) and only moderate valuation support with a low dividend yield.
Advanced Enzyme Technologies Ltd (ADVENZYMES) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 31.72B
- Dividend Yield
- 0.48%
- Average Volume (3M)
- 9,761
- Price to Earnings (P/E)
- 18.4
- Beta (1Y)
- 0.94
- Revenue Growth
- 10.31%
- EPS Growth
- 15.98%
- Country
- India
- Employees
- 409
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Chemicals - Specialty
Advanced Enzyme Technologies Ltd Business Overview & Revenue Model
Company Description
Advanced Enzyme Technologies Limited, headquartered in Thane, India, is a global company engaged in the research, development, manufacturing, and marketing of enzymes and probiotics. Its operations span India, the United States, Asia, and Europe. The...
Advanced Enzyme Technologies Ltd Financial Statement Overview
Summary
Strong overall fundamentals supported by an exceptionally conservative balance sheet (very low leverage), healthy profitability (net margins generally ~20%+), and reliable operating cash generation. Offsetting factors include margin compression versus peak FY2021–FY2022 levels and uneven year-to-year free cash flow growth.
Income Statement
78PositiveBalance Sheet
92Very PositiveCash Flow
83Very Positive| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.80B | 7.46B | 6.37B | 6.23B | 5.41B | 5.29B |
| Gross Profit | 3.66B | 3.50B | 3.07B | 4.64B | 3.98B | 4.09B |
| EBITDA | 2.63B | 2.75B | 2.27B | 2.27B | 1.79B | 2.09B |
| Net Income | 1.71B | 1.69B | 1.31B | 1.33B | 1.06B | 1.20B |
Balance Sheet | ||||||
| Total Assets | 19.06B | 18.39B | 16.21B | 15.35B | 14.22B | 12.68B |
| Cash, Cash Equivalents and Short-Term Investments | 6.73B | 7.00B | 5.88B | 5.48B | 4.86B | 3.74B |
| Total Debt | 536.99M | 320.09M | 393.50M | 473.08M | 334.99M | 347.30M |
| Total Liabilities | 1.86B | 1.56B | 1.53B | 1.64B | 1.38B | 1.27B |
| Stockholders Equity | 16.65B | 16.32B | 14.21B | 13.24B | 12.35B | 10.89B |
Cash Flow | ||||||
| Free Cash Flow | 0 | 1.20B | 1.15B | 990.56M | 1.02B | 941.15M |
| Operating Cash Flow | 0 | 1.73B | 1.49B | 1.41B | 1.40B | 1.22B |
| Investing Cash Flow | 0 | -923.39M | -990.44M | -646.49M | -2.98B | -249.12M |
| Financing Cash Flow | 0 | -679.45M | -692.02M | -592.38M | -257.98M | -273.75M |
Advanced Enzyme Technologies Ltd Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ADVENZYMES, the sentiment is Neutral. The current price of 281.10 is above the 20-day moving average (MA) of 272.11, above the 50-day MA of 278.34, and below the 200-day MA of 308.21, indicating a neutral trend. The MACD of 2.62 indicates Negative momentum. The RSI at 55.03 is Neutral, neither overbought nor oversold. The STOCH value of 51.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:ADVENZYMES.
Advanced Enzyme Technologies Ltd Peers Comparison
Overall Rating
IN:ADVENZYMES70Outperform
IN:ROSSARI65Neutral
IN:AVTNPL63Neutral
IN:JUBLINGREA61Neutral
IN:NEOGEN55Neutral
IN:VIDHIING55Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 70Outperform | INR 31.48B | 18.39 | ― | 0.48% | 10.31% | 15.98% | |
| 65Neutral | INR 23.89B | 15.69 | ― | 0.12% | 19.76% | 11.74% | |
| 63Neutral | INR 15.72B | 15.53 | ― | 0.77% | 41.25% | 65.19% | |
| 61Neutral | INR 93.24B | 26.42 | ― | 0.85% | 15.41% | 21.76% | |
| 55Neutral | INR 84.02B | 186.22 | ― | 0.04% | 26.66% | 51.16% | |
| 55Neutral | INR 15.36B | 25.22 | ― | 1.95% | 34.77% | 25.92% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:ADVENZYMES | Advanced Enzyme Technologies Ltd | 281.10 | -34.54 | -10.94% | |
| IN:AVTNPL | AVT Natural Products Limited | 103.20 | 35.41 | 52.23% | |
| IN:JUBLINGREA | Jubilant Ingrevia Ltd. | 585.40 | -129.38 | -18.10% | |
| IN:NEOGEN | Neogen Chemicals Ltd. | 2796.55 | 1552.55 | 124.80% | |
| IN:ROSSARI | Rossari Biotech Ltd | 431.30 | -183.70 | -29.87% | |
| IN:VIDHIING | Vidhi Specialty Food Ingredients Ltd | 305.30 | -62.80 | -17.06% |
Advanced Enzyme Technologies Ltd Corporate Events
Advanced Enzyme promoter group member seeks shift to public shareholder status
Advanced Enzyme Technologies has disclosed that a promoter group member, Snehal Shamsunder Soni, holding 15,000 equity shares amounting to 0.01% of the company’s share capital, has formally requested reclassification from the promoter group category...
Advanced Enzymes Promoter Group Member Seeks Reclassification as Public Shareholder
Advanced Enzyme Technologies has informed the stock exchanges that it received a request from promoter group member Pratik Prakash Kokane to reclassify his 10,000 shares, representing 0.01% of equity, from promoter group to public shareholder under S...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 03, 2026
